Eli Lilly announced an agreement to acquireVersanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases for $1.925B in cash.
Versanis’ lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to block activin and myostatin signaling. Bimagrumab is currently being assessed in the BELIEVE Phase 2b study alone and in combination with semaglutide in adults who are overweight or obese.
Combining incretins with bimagrumab has the potential to further reduce fat mass while preserving muscle mass and may lead to better outcomes for people living with obesity and obesity-related complications.
As an extremely aggressive form of skin cancer, cutaneous melanoma is still associated with a high mortality rate. Enormous progress has recently been made in
Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) — Silo
Eli Lilly Acquires Obesity Drug Maker Versanis for $1.9B – M&A
by Fred Pennic Leave a Comment
What You Should Know:
Pharmalittle: We’re reading about GLP-1 drugs’ safety, Novartis nixing a deal, and more
And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal
Researchers discover new option to target the metastatic capacity of melanoma cells
As an extremely aggressive form of skin cancer, cutaneous melanoma is still associated with a high mortality rate. Enormous progress has recently been made in
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA – Psychedelic Alpha
Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) — Silo